MX2019000498A - Regímenes de dosis de antagonista de oxitocina para promover la implantación embrionaria y prevenir abortos espontaneos. - Google Patents
Regímenes de dosis de antagonista de oxitocina para promover la implantación embrionaria y prevenir abortos espontaneos.Info
- Publication number
- MX2019000498A MX2019000498A MX2019000498A MX2019000498A MX2019000498A MX 2019000498 A MX2019000498 A MX 2019000498A MX 2019000498 A MX2019000498 A MX 2019000498A MX 2019000498 A MX2019000498 A MX 2019000498A MX 2019000498 A MX2019000498 A MX 2019000498A
- Authority
- MX
- Mexico
- Prior art keywords
- embryo implantation
- dosing regimens
- oxytocin antagonist
- preventing miscarriage
- methods
- Prior art date
Links
- 239000003336 oxytocin antagonist Substances 0.000 title abstract 3
- 229940121361 oxytocin antagonists Drugs 0.000 title abstract 3
- 206010000234 Abortion spontaneous Diseases 0.000 title abstract 2
- 230000032692 embryo implantation Effects 0.000 title abstract 2
- 208000015994 miscarriage Diseases 0.000 title abstract 2
- 208000000995 spontaneous abortion Diseases 0.000 title abstract 2
- 230000001737 promoting effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- 210000001161 mammalian embryo Anatomy 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- OLUJSZLBWZWGJT-KOXKPCSVSA-N [(2s,4e)-2-(hydroxymethyl)-4-methoxyiminopyrrolidin-1-yl]-[4-(2-methylphenyl)phenyl]methanone Chemical compound C1C(=N/OC)/C[C@@H](CO)N1C(=O)C1=CC=C(C=2C(=CC=CC=2)C)C=C1 OLUJSZLBWZWGJT-KOXKPCSVSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002357 endometrial effect Effects 0.000 abstract 1
- 230000004720 fertilization Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- HGAWACRPWVRCFI-UHFFFAOYSA-N n-pyrrolidin-3-ylidenehydroxylamine Chemical class ON=C1CCNC1 HGAWACRPWVRCFI-UHFFFAOYSA-N 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pregnancy & Childbirth (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- External Artificial Organs (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pyrrole Compounds (AREA)
Abstract
La invención proporciona composiciones y métodos para el uso de antagonistas de oxitocina, tales como derivados de pirrolidin-3-ona oxima sustituidos, entre otros compuestos, en el tratamiento de sujetos sometidos a un tratamiento de transferencia embrionaria. Las composiciones y métodos de la invención se pueden usar para la administración a sujetos de dosis con antagonistas de oxitocina, que incluyen (3Z,5S)-5-(hidroximetil)-1-[(2'-metil-1,1'-bifenil- 4-il)carbonil]pirrolidin-3-ona 0-metiloxima, entre otros, para mejorar la receptividad endometrial y reducir la probabilidad de falla en la implantación embrionaria y un aborto espontáneo después de, por ejemplo, procedimientos de transferencia embrionaria mediante fertilización in vitro (IVF) e inyección intracitoplasmática de espermatozoides (ICSI).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662365147P | 2016-07-21 | 2016-07-21 | |
| US201762527721P | 2017-06-30 | 2017-06-30 | |
| PCT/EP2017/068378 WO2018015497A2 (en) | 2016-07-21 | 2017-07-20 | Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019000498A true MX2019000498A (es) | 2019-09-16 |
Family
ID=59501409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000498A MX2019000498A (es) | 2016-07-21 | 2017-07-20 | Regímenes de dosis de antagonista de oxitocina para promover la implantación embrionaria y prevenir abortos espontaneos. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20190247361A1 (es) |
| EP (2) | EP4056178A1 (es) |
| JP (2) | JP7036791B2 (es) |
| KR (2) | KR20190039725A (es) |
| CN (3) | CN115569132A (es) |
| AU (2) | AU2017300026B2 (es) |
| BR (1) | BR112019001047A2 (es) |
| CA (1) | CA3031252A1 (es) |
| ES (1) | ES2898778T3 (es) |
| IL (1) | IL264243B2 (es) |
| MA (1) | MA52548A (es) |
| MX (1) | MX2019000498A (es) |
| SG (1) | SG11201900461UA (es) |
| UA (1) | UA127283C2 (es) |
| WO (1) | WO2018015497A2 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020340670A1 (en) * | 2019-09-03 | 2022-04-07 | ObsEva S.A. | Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3780725A (en) | 1971-03-04 | 1973-12-25 | Smith Kline Instr | Fetal heartbeat monitoring system with plural transducers in one plane and at different angles thereto |
| NO753203L (es) | 1974-11-11 | 1976-07-21 | Carter Wallace | |
| IL56342A (en) | 1978-12-29 | 1982-05-31 | Zer Tamar | Method and means for determining human chorionic gonadotropin in urine |
| SE430885B (sv) | 1980-03-24 | 1983-12-19 | Ferring Ab | Oxytocin-derivat |
| US4437467A (en) | 1981-12-11 | 1984-03-20 | American Home Products Corporation | Apparatus for monitoring fetal heartbeat and the like |
| US4504469A (en) | 1982-12-21 | 1985-03-12 | Ferring Ab | Vasotocin derivatives |
| US4720455A (en) | 1985-09-06 | 1988-01-19 | Pitman-Moore, Inc. | Progesterone assay method for mammals and monoclonal antibody therefor |
| AU6417790A (en) | 1989-09-22 | 1991-04-18 | Tsi-Madison Research Institute | Method and compositions for one-step cryopreservation of embryos |
| SE9604341D0 (sv) | 1996-11-26 | 1996-11-26 | Ferring Bv | Hepta-peptide oxytocin analogue |
| DE69942804D1 (de) | 1998-08-11 | 2010-11-11 | Univ Hawaii | Transgenese in säugetieren durch intracytoplasmatische injektion von spermien |
| IL160780A0 (en) | 2001-09-12 | 2004-08-31 | Applied Research Systems | USE OF hCG IN THE MANUFACTURE OF A MEDICAMENT |
| GB0130677D0 (en) | 2001-12-21 | 2002-02-06 | Glaxo Group Ltd | Medicaments and novel compounds |
| WO2003072597A1 (en) | 2002-02-27 | 2003-09-04 | Ferring Bv | Intermediates and methods for making heptapeptide oxytocin analogues |
| JP2005530818A (ja) | 2002-06-07 | 2005-10-13 | アレス トレーディング ソシエテ アノニム | 卵巣過剰刺激の制御方法及び当該方法に利用する医薬キット |
| UA78058C2 (en) | 2002-07-05 | 2007-02-15 | Applied Research Systems | Pyrrolidine derivative as oxitocin antagonists |
| GB0314738D0 (en) | 2003-06-24 | 2003-07-30 | Glaxo Group Ltd | Novel compounds |
| EP1646389B1 (en) | 2003-07-07 | 2008-09-10 | Neurocrine Biosciences, Inc. | Pyrimidine-2,4-dione derivatives as gonadotropin-releasing hormone receptor antagonists |
| GB0414093D0 (en) | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
| MX2007014022A (es) * | 2005-05-10 | 2008-02-07 | Ferring Int Ct Sa | Uso de antagonistas de oxitocina y/o vasopresina en la reproduccion asistida. |
| WO2008051620A2 (en) | 2006-10-24 | 2008-05-02 | University Of Hawaii | Methods and compositions for intracytoplasmic sperm injection-mediated transgenesis |
| US7989217B2 (en) | 2007-03-29 | 2011-08-02 | Ameritek Usa, Inc. | Method for determining hCG levels in fluid samples |
| EP2315826A1 (en) | 2008-07-23 | 2011-05-04 | Mariposa Biotechnology, Inc. | Automated system for cryopreservation of oocytes, embryos, or blastocysts |
| US9201077B2 (en) * | 2009-07-27 | 2015-12-01 | Colorado State University Research Foundation | Direct enzyme immunoassay for measurement of serum progesterone levels |
| US8716286B2 (en) | 2009-10-30 | 2014-05-06 | Glaxo Group Limited | Crystalline forms of (3R, 6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione |
| WO2013158658A1 (en) | 2012-04-16 | 2013-10-24 | Cornell University | Automated intracytoplasmic sperm injection assisted fertilization system |
| US8937139B2 (en) | 2012-10-25 | 2015-01-20 | Chevron Phillips Chemical Company Lp | Catalyst compositions and methods of making and using same |
| JP2016503324A (ja) * | 2012-11-26 | 2016-02-04 | フェリング ベスローテン フェンノートシャップ | 画像解析を使用して子宮収縮レベルを診断するための方法およびシステム |
| EP2845850A1 (en) | 2013-09-10 | 2015-03-11 | ObsEva S.A. | Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists |
| EP2886107A1 (en) | 2013-12-17 | 2015-06-24 | ObsEva S.A. | Oral formulations of pyrrolydine derivatives |
| EA201891873A1 (ru) * | 2014-07-02 | 2019-04-30 | Обсева Са | Кристаллический о-метилоксим (3z,5s)-5-(гидроксиметил)-1-[(2'-метил-1,1'-бифенил-4-ил)карбонил]пирролидин-3-он, полезный в способах лечения состояний, связанных с активностью ot-r |
| PL3037101T3 (pl) | 2014-12-22 | 2019-06-28 | Ferring B.V. | Terapia antagonistą receptora oksytocyny w fazie lutealnej w celu implantacji i uzyskania ciąży u kobiet poddawanych technikom wspomaganego rozrodu |
| EP3359557A1 (en) | 2015-10-06 | 2018-08-15 | Ferring B.V. | New methods for making barusiban and its intermediates |
-
2017
- 2017-07-20 ES ES17746025T patent/ES2898778T3/es active Active
- 2017-07-20 EP EP21192306.5A patent/EP4056178A1/en active Pending
- 2017-07-20 BR BR112019001047-5A patent/BR112019001047A2/pt unknown
- 2017-07-20 UA UAA201900447A patent/UA127283C2/uk unknown
- 2017-07-20 MX MX2019000498A patent/MX2019000498A/es unknown
- 2017-07-20 SG SG11201900461UA patent/SG11201900461UA/en unknown
- 2017-07-20 JP JP2019502231A patent/JP7036791B2/ja active Active
- 2017-07-20 WO PCT/EP2017/068378 patent/WO2018015497A2/en unknown
- 2017-07-20 CA CA3031252A patent/CA3031252A1/en active Pending
- 2017-07-20 MA MA052548A patent/MA52548A/fr unknown
- 2017-07-20 EP EP17746025.0A patent/EP3487493B1/en active Active
- 2017-07-20 US US16/318,413 patent/US20190247361A1/en active Pending
- 2017-07-20 KR KR1020197005126A patent/KR20190039725A/ko active Application Filing
- 2017-07-20 KR KR1020237040950A patent/KR20230165386A/ko not_active Application Discontinuation
- 2017-07-20 CN CN202211236862.5A patent/CN115569132A/zh active Pending
- 2017-07-20 CN CN201780055051.6A patent/CN109689048B/zh active Active
- 2017-07-20 AU AU2017300026A patent/AU2017300026B2/en active Active
- 2017-07-20 CN CN202211237071.4A patent/CN115590849A/zh active Pending
-
2019
- 2019-01-14 IL IL264243A patent/IL264243B2/en unknown
-
2022
- 2022-03-03 JP JP2022032889A patent/JP2022078194A/ja active Pending
-
2023
- 2023-09-29 AU AU2023237170A patent/AU2023237170A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7036791B2 (ja) | 2022-03-15 |
| IL264243A (en) | 2019-02-28 |
| CN109689048A (zh) | 2019-04-26 |
| IL264243B2 (en) | 2023-02-01 |
| JP2022078194A (ja) | 2022-05-24 |
| WO2018015497A3 (en) | 2018-03-01 |
| CN115590849A (zh) | 2023-01-13 |
| CN115569132A (zh) | 2023-01-06 |
| MA52548A (fr) | 2021-05-26 |
| CN109689048B (zh) | 2022-10-28 |
| UA127283C2 (uk) | 2023-07-12 |
| BR112019001047A2 (pt) | 2019-04-30 |
| KR20230165386A (ko) | 2023-12-05 |
| AU2017300026A1 (en) | 2019-02-28 |
| WO2018015497A2 (en) | 2018-01-25 |
| EP3487493B1 (en) | 2021-09-01 |
| AU2017300026B2 (en) | 2023-07-13 |
| CA3031252A1 (en) | 2018-01-25 |
| US20190247361A1 (en) | 2019-08-15 |
| IL264243B (en) | 2022-10-01 |
| AU2023237170A1 (en) | 2023-10-19 |
| SG11201900461UA (en) | 2019-02-27 |
| KR20190039725A (ko) | 2019-04-15 |
| JP2019523251A (ja) | 2019-08-22 |
| ES2898778T3 (es) | 2022-03-08 |
| EP3487493A2 (en) | 2019-05-29 |
| EP4056178A1 (en) | 2022-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551870A1 (en) | Tetracyclic heteroaryl compounds | |
| PH12017502425A1 (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| PH12018500097A1 (en) | Combination of pd-1 antagonist with an egfr inhibitor | |
| PH12017500583A1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| CL2017002686A1 (es) | Métodos para tratar o prevenir dolor de cabeza por migraña | |
| CL2018001031A1 (es) | Inhibidores de ferroportina novedosos | |
| MX2016010034A (es) | Inhibidores de dihidropirrolopiridina de receptor huerfano relacionado-gamma. | |
| MX2017010858A (es) | Composicion para el tratamiento de enfermedades relacionadas con la interleucina 6. | |
| NZ725006A (en) | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns | |
| BR112015003188A2 (pt) | Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| PH12014502040A1 (en) | Heterocyclyl compounds | |
| EA201691404A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов бромодомена | |
| MX371068B (es) | ((3z,5s)-5-(hidroximetil)-1-[(2'-metil-1,1'-bifenil-4-il)carbonil ]pirrolidin-3-ona o-metiloxima cristalina y métodos de uso de la misma. | |
| EA201992612A1 (ru) | Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза | |
| TN2020000009A1 (en) | Estrogen receptor modulators | |
| PH12020550228A1 (en) | Epidermal growth factor receptor inhibitors | |
| PH12017502100A1 (en) | Selective progesterone receptor modulator (sprm) regimen | |
| MX2019000498A (es) | Regímenes de dosis de antagonista de oxitocina para promover la implantación embrionaria y prevenir abortos espontaneos. | |
| CL2016001744A1 (es) | Compuestos derivados de 1-bencil-3-(4-(4-oxifenil)piperidin-1-il)pirrolidin-2-ona, ligandos para el receptor de nmda subtipo nr2b; composición farmacéutica; y su uso para el tratamiento de trastornos del sistema nervioso central | |
| BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| BR112018073396A2 (pt) | combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| EA201990057A1 (ru) | Схемы применения антагониста окситоцина для содействия имплантации эмбриона и предотвращения выкидыша | |
| MX2020007326A (es) | Regimen de dosificacion de siponimod. | |
| EA202190966A1 (ru) | Пролекарства антагонистов cgrp | |
| TW201613921A (en) | Serine derivatives as ghrelin receptor agonists |